1
|
Meeuwes FO, Brink M, Plattel W, Van der Poel MWM, Kersten MJ, Wondergem M, Böhmer L, Woei-A-Jin FJSH, Visser O, Oostvogels R, Jansen PM, Neelis KJ, Crijns APG, Daniëls LA, Snijders TJF, Vermaat JSP, Huls GA, Nijland M. Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands. Haematologica 2024; 109:1163-1170. [PMID: 37794805 PMCID: PMC10985449 DOI: 10.3324/haematol.2023.283174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2023] [Indexed: 10/06/2023] Open
Abstract
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of mature T-cell neoplasms with an unfavorable prognosis; presentation with stage I(E) disease is uncommon. In clinical practice, an abbreviated chemotherapy treatment regimen combined with radiotherapy (combined modality treatment [CMT]) is commonly used, although evidence from clinical trials is lacking. The aim of this nationwide population-based cohort study is to describe first-line treatment and outcome of patients with stage I(E) PTCL. All newly diagnosed patients ≥18 years with stage I(E) anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma NOS (PTCL not otherise specified [NOS]) in 1989-2020 were identified in the Netherlands Cancer Registry. Patients were categorized according to treatment regimen, i.e., chemotherapy (CT), radiotherapy (RT), CMT, other therapy and no treatment. The primary endpoint was overall survival (OS). Patients with stage I(E) ALCL, AITL and PTCL NOS (n=576) were most commonly treated with CMT (28%) or CT (29%), 2% underwent SCT. RT only was given in 18%, and 8% received other therapy and 16% no treatment. Overall, the 5-year OS was 59%. According to subtype, 5-year OS was superior for ALCL as compared to PTCL NOS and AITL (68% vs. 55% and 52%, respectively; P=0.03). For patients treated with CMT, 5-year OS was significantly higher (72%) as compared to patients treated with either CT or RT alone (55% and 55%, respectively; P<0.01). In multivariable analysis, age per year increment (hazard ratio [HR] =1.06, 95% confidence interval [CI]: 1.05-1.07), male sex (HR=1.53, 95% CI: 1.23-1.90), and CT, or no treatment (HR=1.64, 95% CI: 1.21-2.21, and HR=1.55, 95% CI: 1.10-2.17, respectively) were associated with a higher risk of mortality. For stage I(E) ALCL, AITL and PTCL NOS, 5-year OS is 59%, comparing favorably to historical outcome in advanced-stage disease. Superior outcome estimates were observed in patients treated with CMT.
Collapse
Affiliation(s)
- Frederik O Meeuwes
- Department of Hematology, Treant Hospital, Emmen, The Netherlands; Department of Hematology, University Medical Center Groningen, Groningen
| | - Mirian Brink
- Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht
| | - Wouter Plattel
- Department of Hematology, University Medical Center Groningen, Groningen
| | - Marjolein W M Van der Poel
- Department of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht
| | - Marie José Kersten
- Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam
| | - Mariëlle Wondergem
- Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam
| | - Lara Böhmer
- Department of Hematology, Haga Hospital, The Hague
| | | | - Otto Visser
- Department of Hematology, Isala Hospital, Zwolle
| | - Rimke Oostvogels
- Department of Hematology, University Medical Center Utrecht, Utrecht
| | - Patty M Jansen
- Department of Pathology, Leiden University Medical Center, Leiden
| | - Karen J Neelis
- Department of Radiotherapy, Leiden University Medical Center, Leiden
| | - Anne P G Crijns
- Department of Radiotherapy, University Medical Center Groningen, Groningen
| | - Laurien A Daniëls
- Department of Radiotherapy, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam
| | | | | | - Gerwin A Huls
- Department of Hematology, University Medical Center Groningen, Groningen
| | - Marcel Nijland
- Department of Hematology, University Medical Center Groningen, Groningen.
| |
Collapse
|
2
|
Luining W, Oprea-Lager D, Vis A, Van Moorselaar R, Knol R, Wondergem M, Boellaard R, Cysouw M. Validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00162-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
3
|
Richters A, van Ginkel N, Meijer R, Wondergem M, Boellaard T, Kiemeney L, Witjes J, Aben K, Van Rhijn B, Mertens L. The influence of FDG-PET/CT on the nodal stage and treatment in muscle-invasive bladder cancer: A nationwide cohort study. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01092-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
4
|
Meeuwes FO, Brink M, van der Poel MWM, Kersten MJ, Wondergem M, Mutsaers PGNJ, Böhmer L, Woei-A-Jin S, Visser O, Oostvogels R, Jansen PM, Diepstra A, Snijders TJF, Plattel WJ, Huls GA, Vermaat JSP, Nijland M. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis. Eur J Cancer 2022; 176:100-109. [PMID: 36208568 DOI: 10.1016/j.ejca.2022.09.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 09/08/2022] [Accepted: 09/08/2022] [Indexed: 12/15/2022]
Abstract
BACKGROUND Patients with angioimmunoblastic T-cell lymphoma (AITL) are treated with cyclophosphamide, doxorubicin, vincristine and prednisone with or without etoposide (CHO(E)P). In the majority of cases, Epstein-Barr virus (EBV)-positive B-cells are present in the tumour. There is paucity of research examining the effect of rituximab when added to CHO(E)P. In this nationwide, population-based study, we analysed the impact of rituximab on overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) of patients with AITL. METHODS Patients with AITL diagnosed between 2014 and 2020 treated with ≥one cycle of CHO(E)P with or without rituximab were identified in the Netherlands Cancer Registry. Survival follow-up was up to 1st February 2022. Baseline characteristics, best response during first-line treatment and survival were collected. PFS was defined as the time from diagnosis to relapse or to all-cause-death. OS was defined as the time from diagnosis to all-cause-death. Multivariable analysis for the risk of mortality was performed using Cox regression. FINDINGS Out of 335 patients, 146 patients (44%) received R-CHO(E)P. Rituximab was more frequently used in patients with a B-cell infiltrate (71% versus 89%, p < 0·01). The proportion of patients who received autologous stem cell transplantation (ASCT) was similar between CHO(E)P and R-CHO(E)P (27% versus 30%, respectively). The ORR and 2-year PFS for patients who received CHO(E)P and R-CHO(E)P were 71% and 78% (p = 0·01), and 40% and 45% (p = 0·12), respectively. The 5-year OS was 47% and 40% (p = 0·99), respectively. In multivariable analysis, IPI-score 3-5, no B-cell infiltrate and no ASCT were independent prognostic factors for risk of mortality, whereas the use of rituximab was not. INTERPRETATION Although the addition of rituximab to CHO(E)P improved ORR for patients with AITL, the PFS and OS did not improve.
Collapse
Affiliation(s)
- Frederik O Meeuwes
- Department of Hematology, Treant Hospital, Emmen, the Netherlands; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands
| | - Mirian Brink
- Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands
| | - Marjolein W M van der Poel
- Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Marie José Kersten
- Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
| | - Mariëlle Wondergem
- Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
| | - Pim G N J Mutsaers
- Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Lara Böhmer
- Department of Hematology, Haga Hospital, The Hague, the Netherlands
| | - Sherida Woei-A-Jin
- Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Otto Visser
- Department of Hematology, Isala Hospital, Zwolle, the Netherlands
| | - Rimke Oostvogels
- Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Patty M Jansen
- Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands
| | - Arjan Diepstra
- Department of Pathology, University Medical Center Groningen, Groningen, the Netherlands
| | - Tjeerd J F Snijders
- Department of Hematology, Medisch Spectrum Twente, Enschede, the Netherlands
| | - Wouter J Plattel
- Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands
| | - Gerwin A Huls
- Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands
| | - Joost S P Vermaat
- Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands
| | - Marcel Nijland
- Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.
| |
Collapse
|
5
|
Hagens M, Luining W, Jager A, Wondergem M, Donswijk M, Oprea-Lager D, Vis A, Van Leeuwen P, Van Der Poel H. The diagnostic added value of PSMA PET/CT in men with newly diagnosed ISUP grade group 3 prostate cancer. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02466-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
6
|
van Ginkel N, Van Gennep E, Boellaard T, Wondergem M, De Reijke T, Vis A, Van Rhijn B, Mertens L. The role of 18F-FDG-PET/CT for staging patients with high risk non-muscle invasive bladder cancer before radical cystectomy. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02378-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
7
|
Braam AM, Wondergem M, Crul M. Severe Tissue Necrosis after Low-Concentration Cisplatin Extravasation: A Case Report and Review of Expert Guidelines and Literature. Case Rep Oncol 2022; 15:902-908. [PMID: 36825098 PMCID: PMC9941778 DOI: 10.1159/000525525] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Accepted: 06/10/2022] [Indexed: 11/19/2022] Open
Abstract
A 65-year-old man was treated with a course of rituximab, cisplatin, and cytarabine. During the second cycle, a volume of 40-50 mL of 0.3 mg/mL cisplatin was extravasated. The patient was treated with a cold pack multiple times a day and cutaneous application of dimethyl sulfoxide cream three times a day for a week. In the months after the extravasation, the patient suffered from worsened swelling and redness and a black crust had formed on the wound. The patient was diagnosed with chemical phlebitis. After watchful waiting for 3 months, antibiotic therapy was started. After 7 months, the wound had healed. On the contrary to what is described in our case, no extravasation guideline classifies cisplatin in a concentration lower than 0.4 mg/ml as a vesicant. The different guidelines also present conflicting recommendations on how to treat the extravasation of cisplatin. In three previous case reports, severe effects of cisplatin extravasation after infusion at low concentration were described as well. We recommend that the findings from our case report are incorporated into extravasation guidelines to ensure optimal treatment of cisplatin extravasations.
Collapse
Affiliation(s)
- Anouk M. Braam
- aDepartment of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Center, location Vrije Universiteit, Amsterdam, The Netherlands,*Anouk M. Braam,
| | - Mariëlle Wondergem
- bDepartment of Hematology, Amsterdam University Medical Center, location Vrije Universiteit, Amsterdam, The Netherlands
| | - Mirjam Crul
- aDepartment of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Center, location Vrije Universiteit, Amsterdam, The Netherlands
| |
Collapse
|
8
|
Hagens M, Oprea-Lager D, Vis A, Wondergem M, Donswijk M, Meijer D, Emmett L, Van Leeuwen P, Van Der Poel H. Reproducibility of tumor staging depends on the applied PSMA-radiotracer - A retrospective analysis on the interobserver variability of PSMA-PET/CT. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)03074-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
9
|
Jansen BHE, Bodar YJL, Zwezerijnen GJC, Meijer D, van der Voorn JP, Nieuwenhuijzen JA, Wondergem M, Roeleveld TA, Boellaard R, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN. Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial. Eur J Nucl Med Mol Imaging 2021; 48:509-520. [PMID: 32789599 PMCID: PMC7835187 DOI: 10.1007/s00259-020-04974-w] [Citation(s) in RCA: 54] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Accepted: 07/23/2020] [Indexed: 01/01/2023]
Abstract
PURPOSE The detection of lymph-node metastases (N1) with conventional imaging such as magnetic resonance imaging (MRI) and computed tomography (CT) is inadequate for primarily diagnosed prostate cancer (PCa). Prostate-specific membrane antigen (PSMA) PET/CT is successfully introduced for the staging of (biochemically) recurrent PCa. Besides the frequently used 68gallium-labelled PSMA tracers, 18fluorine-labelled PSMA tracers are available. This study examined the diagnostic accuracy of 18F-DCFPyL (PSMA) PET/CT for lymph-node staging in primary PCa. METHODS This was a prospective, multicentre cohort study. Patients with primary PCa underwent 18F-DCFPyL PET/CT prior to robot-assisted radical prostatectomy (RARP) with extended pelvic lymph-node dissection (ePLND). Patients were included between October 2017 and January 2020. A Memorial Sloan Kettering Cancer Centre (MSKCC) nomogram risk probability of ≥ 8% of lymph-node metastases was set to perform ePLND. All images were reviewed by two experienced nuclear physicians, and were compared with post-operative histopathologic results. RESULTS A total of 117 patients was analysed. Lymph-node metastases (N1) were histologically diagnosed in 17/117 patients (14.5%). The sensitivity, specificity, positive predictive value and negative predictive value for the 18F-DCFPyL PET/CT detection of pelvic lymph-node metastases on a patient level were 41.2% (confidence interval (CI): 19.4-66.5%), 94.0% (CI 86.9-97.5%), 53.8% (CI 26.1-79.6%) and 90.4% (CI 82.6-95.0%), respectively. CONCLUSION 18F-DCFPyL PET/CT showed a high specificity (94.4%), yet a limited sensitivity (41.2%) for the detection of pelvic lymph-node metastases in primary PCa. This implies that current PSMA PET/CT imaging cannot replace diagnostic ePLND. Further research is necessary to define the exact place of PSMA PET/CT imaging in the primary staging of PCa.
Collapse
Affiliation(s)
- B H E Jansen
- Department of Urology, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
- Department of Radiology & Nuclear medicine, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
- Prostate Cancer Network, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
| | - Y J L Bodar
- Department of Urology, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
- Department of Radiology & Nuclear medicine, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
- Prostate Cancer Network, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
| | - G J C Zwezerijnen
- Department of Radiology & Nuclear medicine, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - D Meijer
- Department of Urology, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
- Department of Radiology & Nuclear medicine, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
- Prostate Cancer Network, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - J P van der Voorn
- Department of Pathology, Amsterdam University Medical Centres (VU University), Amsterdam, The Netherlands
| | - J A Nieuwenhuijzen
- Department of Urology, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
- Prostate Cancer Network, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - M Wondergem
- Department of Nuclear medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands
| | - T A Roeleveld
- Prostate Cancer Network, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
- Department of Urology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands
| | - R Boellaard
- Department of Radiology & Nuclear medicine, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - O S Hoekstra
- Department of Radiology & Nuclear medicine, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - R J A van Moorselaar
- Department of Urology, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
- Prostate Cancer Network, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - D E Oprea-Lager
- Department of Radiology & Nuclear medicine, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - A N Vis
- Department of Urology, Amsterdam University Medical Centres (VU University), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
- Prostate Cancer Network, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| |
Collapse
|
10
|
Wondergem M, van der Zant FM, Broos WAM, Roeleveld TA, Donker R, Ten Oever D, Geenen RWF, Knol RJJ. 18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy. Eur J Nucl Med Mol Imaging 2020; 48:521-531. [PMID: 32719916 DOI: 10.1007/s00259-020-04782-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Accepted: 03/19/2020] [Indexed: 12/20/2022]
Abstract
PURPOSE Prostate-specific membrane antigen (PSMA) PET/CT shows better diagnostic performance for detection of lymph node and bone metastases as compared to conventional imaging. Studies of PSMA PET/CT in primary staging comprise highly selected patient cohorts. This study evaluates 18F-DCFPyL PET/CT as first-line imaging modality for primary staging of high-risk prostate cancer. MATERIAL From February 2018 until April 2019, all patients with high-risk prostate cancer received 18F-DCFPyL PET/CT for staging of prostate cancer. Baseline characteristics, findings at 18F-DCFPyL PET/CT, number and type of required additional diagnostic procedures, findings at additional diagnostic procedures, and effects of therapy on PSA levels for all patients treated with curative intent were collected and evaluated. RESULTS One hundred-sixty patients were included in the study of which 90 (56%) had evidence of metastasized disease (N1, M1a, M1b and, M1c in 49%, 28%, 31%, and 3% respectively). Additional diagnostic imaging was needed in 2/160 patients (1%) because of equivocal findings on 18F-DCFPyL PET/CT. Eighty-one patients had evidence of PSMA-positive lymph node metastases, of whom 39 (48%) had no enlarged lymph nodes on CT; 18F-DCFPyL PET detected additional metastatic lymph nodes in 41/42 patients that had evidence of lymph node metastases on CT. 18F-DCFPyL PET altered patients' management in 17% of patients. CONCLUSION 18F-DCFPyL PET/CT can be used as first-line imaging modality for therapy selection in patients with primary high-risk prostate cancer, without need for further diagnostic imaging procedures in the majority of patients.
Collapse
Affiliation(s)
- M Wondergem
- Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Wilhelminalaan 12, 1815 JD, Alkmaar, The Netherlands.
| | - F M van der Zant
- Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Wilhelminalaan 12, 1815 JD, Alkmaar, The Netherlands
| | - W A M Broos
- Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Wilhelminalaan 12, 1815 JD, Alkmaar, The Netherlands
| | - T A Roeleveld
- Department of Urology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands
| | - R Donker
- Department of Radiation Oncology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands
| | - D Ten Oever
- Department of Oncology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands
| | - R W F Geenen
- Department of Radiology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands
| | - R J J Knol
- Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Wilhelminalaan 12, 1815 JD, Alkmaar, The Netherlands
| |
Collapse
|
11
|
Jansen B, Bodar Y, Zwezerijnen G, Nieuwenhuijzen J, Wondergem M, Roeleveld T, Hoektra O, Van Moorselaar J, Oprea-Lager D, Vis A. Prospective evaluation of pelvic lymph node staging with 18fluorine prostate-specific membrane antigen PET/CT prior to extended lymph node dissection in primary prostate cancer – the SALT trial. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33738-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
12
|
Wondergem M, Jansen BHE, van der Zant FM, van der Sluis TM, Knol RJJ, van Kalmthout LWM, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN. Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2019; 46:1911-1918. [PMID: 31230088 PMCID: PMC6647179 DOI: 10.1007/s00259-019-04385-6] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Accepted: 05/30/2019] [Indexed: 01/14/2023]
Abstract
Purpose Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 (168Ga)-labelled radiotracers. Alternatively, fluorine-18 (18F)-labelled PSMA tracers are available, such as 18F-DCFPyL, which offer enhanced image quality and therefore potentially increased detection of small metastases. In this study we evaluate the lesion detection efficacy of 18F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value. Methods A total of 248 consecutive patients were evaluated and underwent scanning with 18F-DCFPyL PET/CT for BCR between November 2016 and 2018 in two hospitals in the Netherlands. Patients were examined after radical prostatectomy (52%), external-beam radiation therapy (42%) or brachytherapy (6%). Imaging was performed 120 min after injection of a median dose of 311 MBq 18F-DCFPyL. Results In 214 out of 248 PET/CT scans (86.3%), at least one lesion suggestive of cancer recurrence was detected (‘positive scan’). Scan positivity increased with higher PSA values: 17/29 scans (59%) with PSA values <0.5 ng/ml; 20/29 (69%) with PSA 0.5 to <1.0 ng/ml; 35/41 (85%) with PSA 1.0 to <2.0 ng/ml; 69/73 (95%) with PSA 2.0 to <5.0 ng/ml; and 73/76 (96%) with PSA ≥5.0 ng/ml. Interestingly, suspicious lesions outside the prostatic fossa were detected in 39–50% of patients with PSA <1.0 ng/ml after radical prostatectomy (i.e. candidates for salvage radiotherapy). Conclusion 18F-DCFPyL PET/CT offers early detection of lesions in patients with BCR, even at PSA levels <0.5 ng/ml. These results appear to be comparable to those reported for 68Ga-PSMA and 18F-PSMA-1007, with potentially increased detection efficacy compared to 68Ga-PSMA for patients with PSA <2.0. Electronic supplementary material The online version of this article (10.1007/s00259-019-04385-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- M Wondergem
- Noordwest Ziekenhuisgroep, Nuclear Medicine, Wilhelminalaan 12, 1815 JD, Alkmaar, the Netherlands
| | - B H E Jansen
- Amsterdam University Medical Centers, VU University, Urology, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands. .,Amsterdam University Medical Centers, VU University, Radiology & Nuclear Medicine, Amsterdam, the Netherlands.
| | - F M van der Zant
- Noordwest Ziekenhuisgroep, Nuclear Medicine, Wilhelminalaan 12, 1815 JD, Alkmaar, the Netherlands
| | - T M van der Sluis
- Amsterdam University Medical Centers, VU University, Urology, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
| | - R J J Knol
- Noordwest Ziekenhuisgroep, Nuclear Medicine, Wilhelminalaan 12, 1815 JD, Alkmaar, the Netherlands
| | - L W M van Kalmthout
- Radiology & Nuclear Medicine, University Medical Center Utrecht, Utrecht, the Netherlands
| | - O S Hoekstra
- Amsterdam University Medical Centers, VU University, Radiology & Nuclear Medicine, Amsterdam, the Netherlands
| | - R J A van Moorselaar
- Amsterdam University Medical Centers, VU University, Urology, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
| | - D E Oprea-Lager
- Amsterdam University Medical Centers, VU University, Radiology & Nuclear Medicine, Amsterdam, the Netherlands
| | - A N Vis
- Amsterdam University Medical Centers, VU University, Urology, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
| |
Collapse
|
13
|
Knol RJJ, Van Der Zant FM, Broos WAM, Lazarenko SV, Wondergem M. P155Relation between stress ECG, 13NH3 PET/CT outcome and the occurrence of cardiac events during follow-up in women with chest pain. Eur Heart J Cardiovasc Imaging 2019. [DOI: 10.1093/ehjci/jez147.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- R J J Knol
- Noordwest Ziekenhuisgroep , Nuclear Medicine, Alkmaar, Netherlands (The)
| | - F M Van Der Zant
- Noordwest Ziekenhuisgroep , Nuclear Medicine, Alkmaar, Netherlands (The)
| | - W A M Broos
- Noordwest Ziekenhuisgroep , Nuclear Medicine, Alkmaar, Netherlands (The)
| | - S V Lazarenko
- Noordwest Ziekenhuisgroep , Nuclear Medicine, Alkmaar, Netherlands (The)
| | - M Wondergem
- Noordwest Ziekenhuisgroep , Nuclear Medicine, Alkmaar, Netherlands (The)
| |
Collapse
|
14
|
Issa D, Dinmohamed A, Wondergem M, Blommestein H, Huijgens P, Lugtenburg P, Visser O, Zweegman S, Chamuleau M. POPULATION-BASED STUDY ON DIFFERENT REGIMENS OF R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA IN THE NETHERLANDS SUPPORTS THE USE OF 6 CYCLES OF R-CHOP21. Hematol Oncol 2019. [DOI: 10.1002/hon.61_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- D. Issa
- Internal Medicine/ Hematology; Jeroen Bosch Hospital; Den Bosch Netherlands
| | - A. Dinmohamed
- 3Department of Research; Netherlands Comprehensive Cancer Organisation; Utrecht Netherlands
| | - M. Wondergem
- Hematology; Amsterdam UMC, Vrije Universiteit Amsterdam; Amsterdam Netherlands
| | - H. Blommestein
- Institute for Medical Technology Assessment; Erasmus School of Health Policy & Management; Rotterdam Netherlands
| | - P. Huijgens
- 3Department of Research; Netherlands Comprehensive Cancer Organisation; Utrecht Netherlands
| | - P. Lugtenburg
- Hematology; Erasmus MC Cancer Institute; Rotterdam Netherlands
| | - O. Visser
- 3Department of Research; Netherlands Comprehensive Cancer Organisation; Utrecht Netherlands
| | - S. Zweegman
- Hematology; Amsterdam UMC, Vrije Universiteit Amsterdam; Amsterdam Netherlands
| | - M. Chamuleau
- Hematology; Amsterdam UMC, Vrije Universiteit Amsterdam; Amsterdam Netherlands
| |
Collapse
|
15
|
van Spronsen MF, Westers TM, Lissenberg-Witte BI, Wondergem M, Ossenkoppele GJ, van de Loosdrecht AA. The non-erythroid myeloblast count rule in myelodysplastic syndromes: fruitful or futile? Haematologica 2019; 104:e547-e550. [PMID: 31004031 DOI: 10.3324/haematol.2018.212563] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Margot F van Spronsen
- Department of Hematology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Cancer Center Amsterdam
| | - Theresia M Westers
- Department of Hematology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Cancer Center Amsterdam
| | - Birgit I Lissenberg-Witte
- Department of Epidemiology and Biostatistics, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Mariëlle Wondergem
- Department of Hematology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Cancer Center Amsterdam
| | - Gert J Ossenkoppele
- Department of Hematology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Cancer Center Amsterdam
| | - Arjan A van de Loosdrecht
- Department of Hematology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Cancer Center Amsterdam
| |
Collapse
|
16
|
Kan H, van der Zant FM, Wondergem M, Knol RJJ. Incidental extra-cardiac findings on 13N-ammonia myocardial perfusion PET/CT. J Nucl Cardiol 2017; 24:1860-1868. [PMID: 28390039 DOI: 10.1007/s12350-017-0824-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Accepted: 02/06/2017] [Indexed: 10/19/2022]
Abstract
BACKGROUND The objective of this study was to describe the prevalence of incidental extra-cardiac findings (IECFs) on myocardial perfusion PET/CTs and the prevalence of potentially clinically relevant and clinically irrelevant IECFs, as well as detection rate of previously unknown malignancies. METHODS AND RESULTS From September 2013 until February 2016, a total of 1397 consecutive patients referred for the evaluation of possible ischemia by 13NH3 PET/CT were prospectively included in a database. IECFs were categorized into three groups: potentially clinically relevant IECFs, IECFs that could potentially cause chest pain, and clinically irrelevant IECFs. Additionally, the prevalence of previously unknown malignancies was determined. In 717 (51%) of these patients, 775 IECFs were reported and 115 IECFs were categorized as potentially clinically relevant in 109 (8%) patients. A total of 145 IECFs that could potentially cause chest pain were detected in 139 (10%) patients and 515 clinically irrelevant IECFs were detected in 469 (34%) of the patients. An unknown primary malignancy was histologically proven in 19 patients (1.4%). CONCLUSIONS IECFs are detected on myocardial perfusion PET/CT in approximately half of the patients. In the present study, IECFs were potentially clinically relevant in 8% of the patients and in 1.4% an unknown malignancy was found, most of which were lung cancers.
Collapse
Affiliation(s)
- H Kan
- Cardiac Imaging Division Alkmaar, Northwest Clinics, Alkmaar, The Netherlands.
- Department of Nuclear Medicine, Northwest Clinics, Wilhelminalaan 12, 1815 JD, Alkmaar, The Netherlands.
| | - F M van der Zant
- Cardiac Imaging Division Alkmaar, Northwest Clinics, Alkmaar, The Netherlands
- Department of Nuclear Medicine, Northwest Clinics, Wilhelminalaan 12, 1815 JD, Alkmaar, The Netherlands
| | - M Wondergem
- Cardiac Imaging Division Alkmaar, Northwest Clinics, Alkmaar, The Netherlands
- Department of Nuclear Medicine, Northwest Clinics, Wilhelminalaan 12, 1815 JD, Alkmaar, The Netherlands
| | - R J J Knol
- Cardiac Imaging Division Alkmaar, Northwest Clinics, Alkmaar, The Netherlands
- Department of Nuclear Medicine, Northwest Clinics, Wilhelminalaan 12, 1815 JD, Alkmaar, The Netherlands
| |
Collapse
|
17
|
Federico M, Caballero D, Marcheselli L, Tarantino V, Sarkozy C, Lopez Guillermo A, Wondergem M, Kimby E, Rusconi C, Zucca E, Montoto S, da Silva M, Aurer I, Paszkiewicz-Kozik E, Cartron G, Morschhauser F, Alcoceba M, Chamuleau M, Lockmer S, Minoia C, Issa D, Alonso S, Conte L, Salles G, Coiffier B. THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_104] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Federico
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - D. Caballero
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Marcheselli
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - V. Tarantino
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - C. Sarkozy
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| | - A. Lopez Guillermo
- Department of Hematology; Hospital Clinic, IDIBAPS, CIBERONC; Barcelona Spain
| | - M. Wondergem
- Department of Hematology; VU University Medical Center; Amsterdam Netherlands
| | - E. Kimby
- Department of Hematology; Karolinska Institute; Stockholm Sweden
| | - C. Rusconi
- Division of Hematology; Niguarda Hospital; Milan Italy
| | - E. Zucca
- Oncology Institute of Southern Switzerland; Ospedale San Giovanni; Bellinzona Switzerland
| | - S. Montoto
- Department of Hematology; Barts Cancer Institute, QMUL; London UK
| | - M.G. da Silva
- Department of Hematology; Instituto Português de Oncologia de Lisboa; Lisbon Portugal
| | - I. Aurer
- Division of Hematology; University Hospital Centre Zagreb; Zagreb Croatia
| | - E. Paszkiewicz-Kozik
- Department of Lymphoid Malignancies; The Maria Sklodowska-Curie Memorial Institute and Oncology Centre; Warszawa Poland
| | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | - F. Morschhauser
- Department of Clinical Hematology, CHU Lille, Unite GRITA; Universite de Lille 2; Lille France
| | - M. Alcoceba
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - M. Chamuleau
- Department of Hematology; VU University Medical Center; Amsterdam Netherlands
| | - S. Lockmer
- Department of Hematology; Karolinska Institute; Stockholm Sweden
| | - C. Minoia
- Haematology Unit, National Cancer Research Centre; Istituto Tumori "Giovanni Paolo II"; Bari Italy
| | - D. Issa
- Department of Hematology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch; Netherlands
| | - S. Alonso
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Conte
- Interdisciplinary Laboratory of Applied Research in Medicine (DReAM); University of Salento; Lecce Italy
| | - G. Salles
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| | - B. Coiffier
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| |
Collapse
|
18
|
Taniguchi Y, Takahashi Y, Toba T, Yamada S, Yokoi K, Kobayashi S, Okajima S, Shimane A, Kawai H, Yasaka Y, Smanio P, Oliveira MA, Machado L, Cestari P, Medeiros E, Fukuzawa S, Okino S, Ikeda A, Maekawa J, Ichikawa S, Kuroiwa N, Yamanaka K, Igarashi A, Inagaki M, Patel K, Mahan M, Ananthasubramaniam K, Mouden M, Yokota S, Ottervanger J, Knollema S, Timmer J, Jager P, Padron K, Peix A, Cabrera L, Pena Bofill V, Valera D, Rodriguez Nande L, Carrillo Hernandez R, Mena Esnard E, Fernandez Columbie Y, Bertella E, Baggiano A, Mushtaq S, Segurini C, Loguercio M, Conte E, Beltrama V, Petulla' M, Andreini D, Pontone G, Guzic Salobir B, Dolenc Novak M, Jug B, Kacjan B, Novak Z, Vrtovec M, Mushtaq S, Pontone G, Bertella E, Conte E, Segurini C, Volpato V, Baggiano A, Formenti A, Pepi M, Andreini D, Ajanovic R, Husic-Selimovic A, Zujovic-Ajanovic A, Mlynarski R, Mlynarska A, Golba K, Sosnowski M, Ameta D, Goyal M, Kumar D, Chandra S, Sethi R, Puri A, Dwivedi SK, Narain VS, Saran RK, Nekolla S, Rischpler C, Nicolosi S, Langwieser N, Dirschinger R, Laugwitz K, Schwaiger M, Goral JL, Napoli J, Forcada P, Zucchiatti N, Damico A, Damico A, Olivieri D, Lavorato M, Dubesarsky E, Montana O, Salgado C, Jimenez-Heffernan A, Ramos-Font C, Lopez-Martin J, Sanchez De Mora E, Lopez-Aguilar R, Manovel A, Martinez A, Rivera F, Soriano E, Maroz-Vadalazhskaya N, Trisvetova E, Vrublevskaya O, Abazid R, Kattea M, Saqqah H, Sayed S, Smettei O, Winther S, Svensson M, Birn H, Jorgensen H, Botker H, Ivarsen P, Bottcher M, Maaniitty T, Stenstrom I, Saraste A, Pikkarainen E, Uusitalo V, Ukkonen H, Kajander S, Bax J, Knuuti J, Choi T, Park H, Lee C, Lee J, Seo Y, Cho Y, Hwang E, Cho D, Sanchez Enrique C, Ferrera C, Olmos C, Jimenez - Ballve A, Perez - Castejon MJ, Fernandez C, Vivas D, Vilacosta I, Nagamachi S, Onizuka H, Nishii R, Mizutani Y, Kitamura K, Lo Presti M, Polizzi V, Pino P, Luzi G, Bellavia D, Fiorilli R, Madeo A, Malouf J, Buffa V, Musumeci F, Rosales S, Puente A, Zafrir N, Shochat T, Mats A, Solodky A, Kornowski R, Lorber A, Boemio A, Pellegrino T, Paolillo S, Piscopo V, Carotenuto R, Russo B, Pellegrino S, De Matteis G, Perrone-Filardi P, Cuocolo A, Piscopo V, Pellegrino T, Boemio A, Carotenuto R, Russo B, Pellegrino S, De Matteis G, Petretta M, Cuocolo A, Amirov N, Ibatullin M, Sadykov A A, Saifullina G, Ruano R, Diego Dominguez M, Rodriguez Gabella T, Diego Nieto A, Diaz Gonzalez L, Garcia-Talavera J, Sanchez Fernandez P, Leen A, Al Younis I, Zandbergen-Harlaar S, Verberne H, Gimelli A, Veltman C, Wolterbeek R, Bax J, Scholte A, Mooney D, Rosenblatt J, Dunn T, Vasaiwala S, Okuda K, Nakajima K, Nystrom K, Edenbrandt L, Matsuo S, Wakabayashi H, Hashimoto M, Kinuya S, Iric-Cupic V, Milanov S, Davidovic G, Zdravkovic V, Ashikaga K, Yoneyama K, Akashi Y, Shugushev Z, Maximkin D, Chepurnoy A, Volkova O, Baranovich V, Faibushevich A, El Tahlawi M, Elmurr A, Alzubaidi S, Sakrana A, Gouda M, El Tahlawi R, Sellem A, Melki S, Elajmi W, Hammami H, Okano M, Kato T, Kimura M, Funasako M, Nakane E, Miyamoto S, Izumi T, Haruna T, Inoko M, Massardo T, Swett E, Fernandez R, Vera V, Zhindon J, Fernandez R, Swett E, Vera V, Zhindon J, Alay R, Massardo T, Ohshima S, Nishio M, Kojima A, Tamai S, Kobayashi T, Murohara T, Burrell S, Van Rosendael A, Van Den Hoogen I, De Graaf M, Roelofs J, Kroft L, Bax J, Scholte A, Rjabceva I, Krumina G, Kalvelis A, Chanakhchyan F, Vakhromeeva M, Kankiya E, Koppes J, Knol R, Wondergem M, Van Der Ploeg T, Van Der Zant F, Lazarenko SV, Bruin VS, Pan XB, Declerck JM, Van Der Zant FM, Knol RJJ, Juarez-Orozco LE, Alexanderson E, Slart R, Tio R, Dierckx R, Zeebregts C, Boersma H, Hillege H, Martinez-Aguilar M, Jordan-Rios A, Christensen TE, Ahtarovski KA, Bang LE, Holmvang L, Soeholm H, Ghotbi AA, Andersson H, Ihlemann N, Kjaer A, Hasbak P, Gulya M, Lishmanov YB, Zavadovskii K, Lebedev D, Stahle M, Hellberg S, Liljenback H, Virta J, Metsala O, Yla-Herttuala S, Saukko P, Knuuti J, Saraste A, Roivainen A, Thackeray J, Wang Y, Bankstahl J, Wollert K, Bengel F, Saushkina Y, Evtushenko V, Minin S, Efimova I, Evtushenko A, Smishlyaev K, Lishmanov Y, Maslov L, Okuda K, Nakajima K, Kirihara Y, Sugino S, Matsuo S, Taki J, Hashimoto M, Kinuya S, Ahmadian A, Berman J, Govender P, Ruberg F, Miller E, Piriou N, Pallardy A, Valette F, Cahouch Z, Mathieu C, Warin-Fresse K, Gueffet J, Serfaty J, Trochu J, Kraeber-Bodere F, Van Dijk J, Mouden M, Ottervanger J, Van Dalen J, Jager P, Zafrir N, Ofrk H, Vaturi M, Shochat T, Hassid Y, Belzer D, Sagie A, Kornowski R, Kaminek M, Metelkova I, Budikova M, Koranda P, Henzlova L, Sovova E, Kincl V, Drozdova A, Jordan M, Shahid F, Teoh Y, Thamen R, Hara N, Onoguchi M, Hojyo O, Kawaguchi Y, Murai M, Udaka F, Matsuzawa Y, Bulugahapitiya DS, Avison M, Martin J, Liu YH, Wu J, Liu C, Sinusas A, Daou D, Sabbah R, Bouladhour H, Coaguila C, Aguade-Bruix S, Pizzi M, Romero-Farina G, Candell-Riera J, Castell-Conesa J, Patchett N, Sverdlov A, Miller E, Daou D, Sabbah R, Bouladhour H, Coaguila C, Smettei O, Abazid R, Boulaamayl El Fatemi S, Sallam L, Snipelisky D, Park J, Ray J, Shapiro B, Kostkiewicz M, Szot W, Holcman K, Lesniak-Sobelga A, Podolec P, Clerc O, Possner M, Liga R, Vontobel J, Mikulicic F, Graeni C, Benz D, Herzog B, Gaemperli O, Kaufmann P. Poster Session 1: Sunday 3 May 2015, 08:30-18:00 * Room: Poster Area. Eur Heart J Cardiovasc Imaging 2015. [DOI: 10.1093/ehjci/jev051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|